1UZF
Complex of the anti-hypertensive drug captopril an the human testicular angiotensin I-converting enzyme
1UZF の概要
| エントリーDOI | 10.2210/pdb1uzf/pdb |
| 関連するPDBエントリー | 1O86 1O8A 1UZE |
| 分子名称 | ANGIOTENSIN CONVERTING ENZYME, 2-acetamido-2-deoxy-beta-D-glucopyranose, ZINC ION, ... (6 entities in total) |
| 機能のキーワード | metalloprotease, hydrolase, inhibitor, captopril, zinc dependant peptidase, anti-hypertensive drug |
| 由来する生物種 | HOMO SAPIENS (HUMAN) |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 68864.94 |
| 構造登録者 | Natesh, R.,Schwager, S.L.U.,Evans, H.R.,Sturrock, E.D.,Acharya, K.R. (登録日: 2004-03-11, 公開日: 2004-07-16, 最終更新日: 2024-10-23) |
| 主引用文献 | Natesh, R.,Schwager, S.L.U.,Evans, H.R.,Sturrock, E.D.,Acharya, K.R. Structural Details on the Binding of Antihypertensive Drugs Captopril and Enalaprilat to Human Testicular Angiotensin I-Converting Enzyme Biochemistry, 43:8718-, 2004 Cited by PubMed Abstract: Angiotensin converting enzyme (ACE) plays a critical role in the circulating or endocrine renin-angiotensin system (RAS) as well as the local regulation that exists in tissues such as the myocardium and skeletal muscle. Here we report the high-resolution crystal structures of testis ACE (tACE) in complex with the first successfully designed ACE inhibitor captopril and enalaprilat, the Phe-Ala-Pro analogue. We have compared these structures with the recently reported structure of a tACE-lisinopril complex [Natesh et al. (2003) Nature 421, 551-554]. The analyses reveal that all three inhibitors make direct interactions with the catalytic Zn(2+) ion at the active site of the enzyme: the thiol group of captopril and the carboxylate group of enalaprilat and lisinopril. Subtle differences are also observed at other regions of the binding pocket. These are compared with N-domain models and discussed with reference to published biochemical data. The chloride coordination geometries of the three structures are discussed and compared with other ACE analogues. It is anticipated that the molecular details provided by these structures will be used to improve the binding and/or the design of new, more potent domain-specific inhibitors of ACE that could serve as new generation antihypertensive drugs. PubMed: 15236580DOI: 10.1021/BI049480N 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






